دورية أكاديمية
أعرض في EDS

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures.

التفاصيل البيبلوغرافية
العنوان: Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures.
المؤلفون: Gao C; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Xiong R; Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China., Zhang ZY; Department of Health Management, Second Affliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Peng H; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Gu YK; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Xu W; Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China., Yang WT; Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China., Liu Y; Department of Clinical Pharmacy, Xinhua Hospital, Clinical Pharmacy Innovation Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China. liuyan@shsmu.edu.cn.; Clinical Pharmacy Innovation Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. liuyan@shsmu.edu.cn., Gao J; Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. gaojiehighclea@smmu.edu.cn.; Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices, Shanghai, 200433, China. gaojiehighclea@smmu.edu.cn., Yin Y; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China. yinyou179@163.com.; Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. yinyou179@163.com.
المصدر: Translational neurodegeneration [Transl Neurodegener] 2024 Aug 27; Vol. 13 (1), pp. 43. Date of Electronic Publication: 2024 Aug 27.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101591861 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9158 (Print) Linking ISSN: 20479158 NLM ISO Abbreviation: Transl Neurodegener Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2012-
مواضيع طبية MeSH: Theranostic Nanomedicine*/methods , Theranostic Nanomedicine*/trends , Nanostructures*/therapeutic use , Neurodegenerative Diseases*/therapy , Neurodegenerative Diseases*/diagnostic imaging, Humans ; Drug Delivery Systems/methods ; Drug Delivery Systems/trends ; Animals
مستخلص: The diagnosis of neurodegenerative diseases (NDDs) remains challenging, and existing therapeutic approaches demonstrate little efficacy. NDD drug delivery can be achieved through the utilization of nanostructures, hence enabling multimodal NDD theranostics. Nevertheless, both biomembrane and non-biomembrane nanostructures possess intrinsic shortcomings that must be addressed by hybridization to create novel nanostructures with versatile applications in NDD theranostics. Hybrid nanostructures display improved biocompatibility, inherent targeting capabilities, intelligent responsiveness, and controlled drug release. This paper provides a concise overview of the latest developments in hybrid nanostructures for NDD theranostics and emphasizes various engineering methodologies for the integration of diverse nanostructures, including liposomes, exosomes, cell membranes, and non-biomembrane nanostructures such as polymers, metals, and hydrogels. The use of a combination technique can significantly augment the precision, intelligence, and efficacy of hybrid nanostructures, therefore functioning as a more robust theranostic approach for NDDs. This paper also addresses the issues that arise in the therapeutic translation of hybrid nanostructures and explores potential future prospects in this field.
(© 2024. The Author(s).)
References: Molecules. 2021 Feb 20;26(4):. (PMID: 33672706)
Int J Pharm. 2022 May 25;620:121720. (PMID: 35413397)
JAMA. 2020 Feb 11;323(6):548-560. (PMID: 32044947)
Int J Pharm. 2021 Sep 5;606:120881. (PMID: 34273426)
ChemMedChem. 2018 Oct 22;13(20):2134-2149. (PMID: 30152914)
Cold Spring Harb Perspect Biol. 2017 Jul 5;9(7):. (PMID: 28062563)
Front Neurol. 2018 Sep 03;9:734. (PMID: 30233484)
Eur J Neurol. 2019 Jan;26(1):27-40. (PMID: 30300457)
Adv Drug Deliv Rev. 2019 Aug;148:3-18. (PMID: 31668648)
Nat Rev Immunol. 2002 Aug;2(8):569-79. (PMID: 12154376)
Am J Med. 2020 Dec;133(12):1380-1390.e2. (PMID: 32682869)
J Control Release. 2022 May;345:147-175. (PMID: 35248646)
Acta Biomater. 2016 Sep 1;41:1-16. (PMID: 27265153)
Lancet Neurol. 2019 Jan;18(1):88-106. (PMID: 30497964)
Nanomedicine (Lond). 2011 Jul;6(5):815-35. (PMID: 21793674)
J Mol Biol. 2023 Jun 15;435(12):168114. (PMID: 37085010)
J Neuroimmune Pharmacol. 2017 Mar;12(1):107-119. (PMID: 27209050)
Front Bioeng Biotechnol. 2020 May 05;8:389. (PMID: 32432095)
Sci Adv. 2020 Dec 11;6(50):. (PMID: 33310840)
Expert Opin Drug Deliv. 2021 Sep;18(9):1261-1290. (PMID: 33793359)
Cell. 2023 Feb 16;186(4):693-714. (PMID: 36803602)
Nanomedicine. 2018 Jan;14(1):1-12. (PMID: 28882675)
Biomaterials. 2020 Mar 2;242:119925. (PMID: 32151860)
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):. (PMID: 28716886)
N Engl J Med. 2001 May 17;344(20):1516-26. (PMID: 11357156)
Neuron. 2009 Apr 16;62(1):42-52. (PMID: 19376066)
Neuron. 2012 Jul 12;75(1):11-25. (PMID: 22794257)
Chem Soc Rev. 2014 Oct 7;43(19):6668-71. (PMID: 25105517)
Neurochem Int. 2021 May;145:105008. (PMID: 33684545)
Int J Biol Macromol. 2020 Nov 1;162:246-261. (PMID: 32531361)
Nat Rev Drug Discov. 2020 Sep;19(9):609-633. (PMID: 32709961)
ACS Nano. 2017 Nov 28;11(11):10883-10893. (PMID: 28960957)
Neuron. 2014 May 21;82(4):756-71. (PMID: 24853936)
Mil Med Res. 2023 Apr 27;10(1):19. (PMID: 37101293)
Int J Mol Sci. 2021 Dec 30;23(1):. (PMID: 35008822)
Nat Rev Neurosci. 2022 Jan;23(1):4-22. (PMID: 34782781)
Regen Biomater. 2021 Jul 18;8(4):rbab033. (PMID: 34285811)
Eur J Pharmacol. 2018 Jul 5;830:115-127. (PMID: 29689247)
Colloids Surf B Biointerfaces. 2018 Jan 1;161:497-507. (PMID: 29128836)
Heliyon. 2021 Dec 16;8(1):e08622. (PMID: 35028441)
Pharmaceutics. 2020 Mar 11;12(3):. (PMID: 32168767)
Drug Deliv. 2020 Dec;27(1):502-518. (PMID: 32228100)
Drug Deliv Transl Res. 2020 Dec;10(6):1729-1747. (PMID: 32683647)
Alzheimers Dement. 2022 Dec;18(12):2481-2492. (PMID: 35142027)
Nanomedicine. 2022 Jul;43:102547. (PMID: 35292367)
Cell. 2023 Sep 28;186(20):4260-4270. (PMID: 37729908)
Nat Rev Neurol. 2021 Mar;17(3):185-192. (PMID: 33483719)
Front Aging Neurosci. 2023 Aug 03;15:1206572. (PMID: 37600514)
Nat Rev Genet. 2018 Jul;19(7):405-418. (PMID: 29713012)
N Engl J Med. 2023 Jan 5;388(1):9-21. (PMID: 36449413)
Ageing Res Rev. 2024 Feb;94:102192. (PMID: 38219962)
Cell Mol Life Sci. 2018 Jan;75(2):193-208. (PMID: 28733901)
Molecules. 2023 Mar 03;28(5):. (PMID: 36903581)
Adv Drug Deliv Rev. 2020;154-155:102-122. (PMID: 32650041)
Nanoscale. 2019 Aug 15;11(32):15057-15071. (PMID: 31369016)
Science. 2003 Apr 18;300(5618):486-9. (PMID: 12702875)
Nanomedicine (Lond). 2011 Apr;6(3):423-36. (PMID: 21542682)
Mult Scler. 2018 Feb;24(2):96-120. (PMID: 29353550)
Nanoscale. 2020 Oct 8;12(38):19939-19952. (PMID: 32991664)
ACS Nano. 2022 Jan 25;16(1):869-884. (PMID: 34985280)
Adv Healthc Mater. 2022 Nov;11(22):e2201150. (PMID: 36074801)
Transl Neurodegener. 2023 Mar 16;12(1):13. (PMID: 36922862)
Physiol Rev. 2010 Jul;90(3):905-81. (PMID: 20664076)
Int J Nanomedicine. 2020 Jul 10;15:4919-4932. (PMID: 32764925)
Front Pharmacol. 2022 Apr 07;13:819516. (PMID: 35462907)
J Control Release. 2015 Dec 28;220(Pt B):600-7. (PMID: 26210440)
Nano Lett. 2019 May 8;19(5):3256-3266. (PMID: 30965009)
Int J Nanomedicine. 2017 May 24;12:3941-3965. (PMID: 28579779)
Transl Neurodegener. 2012 Jan 13;1(1):5. (PMID: 23211024)
ACS Nano. 2021 Feb 23;15(2):2263-2280. (PMID: 33426885)
Nat Rev Neurol. 2023 Oct;19(10):583-598. (PMID: 37644213)
Langmuir. 2016 Apr 19;32(15):3637-44. (PMID: 27023433)
Curr Top Med Chem. 2020;20(11):1029-1041. (PMID: 32148195)
Nano Lett. 2019 Jun 12;19(6):3422-3431. (PMID: 30761901)
Bioact Mater. 2020 Sep 11;6(2):529-542. (PMID: 32995678)
Sci Rep. 2019 Jun 4;9(1):8278. (PMID: 31164665)
Neurol Sci. 2021 Jul;42(7):2653-2660. (PMID: 33846881)
Theranostics. 2023 Jul 16;13(12):4138-4165. (PMID: 37554286)
Adv Sci (Weinh). 2021 Oct;8(20):e2101526. (PMID: 34436822)
Science. 1991 Jun 14;252(5012):1515-22. (PMID: 1675487)
ACS Appl Mater Interfaces. 2023 Feb 8;15(5):6486-6498. (PMID: 36716400)
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):. (PMID: 29358317)
Mol Ther. 2023 May 3;31(5):1207-1224. (PMID: 36245129)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Sep-Oct;15(5):e1907. (PMID: 37248794)
Life Sci. 2021 Dec 15;287:120108. (PMID: 34717909)
Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1452-1462. (PMID: 28891351)
Int J Pharm. 2018 May 30;543(1-2):300-310. (PMID: 29608954)
Trends Mol Med. 2011 Jan;17(1):14-24. (PMID: 20889378)
J Transl Int Med. 2022 Mar 26;10(1):15-17. (PMID: 35702184)
Data Brief. 2015 Nov 25;6:15-9. (PMID: 26759823)
Pharmaceutics. 2021 Jan 19;13(1):. (PMID: 33477972)
معلومات مُعتمدة: 23Y11906600 Science and Technology Innovation Action Plan of Shanghai Science and Technology Commission; 22ZR147750 Natural Science Foundation of Xiaogan Municipality; 2023YJBF-PY13 Innovative Research Team of High-level Local University in Shanghai; 2020YLCYJ-Y02；2020CZWJFW12 Innovative Research Team of High-level Local University in Shanghai; BSCX2023-19；BSCX2022-34 Shanghai Aerospace Science and Technology Innovation Foundation
فهرسة مساهمة: Keywords: Alzheimer's disease; Biomembrane; Diagnosis; Hybrid nanostructure; Neurodegenerative diseases; Parkinson's disease
تواريخ الأحداث: Date Created: 20240827 Date Completed: 20240828 Latest Revision: 20240830
رمز التحديث: 20240830
مُعرف محوري في PubMed: PMC11348682
DOI: 10.1186/s40035-024-00436-7
PMID: 39192378
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-9158
DOI:10.1186/s40035-024-00436-7